Olema Pharmaceuticals Inc (OLMA) - News Archive

Unlocking Potential: New Insights from Olema Oncology’s Phase 1b/2 Study on Palazestrant Plus Ribociclib for ER+/HER2- Metastatic Breast Cancer In a rapidly evolving landscape of targeted therapies, the recent announcem...

Olema Oncology Expands Workforce with Strategic Inducement Grants Amid Positive Market TrendsIn a move signaling continued growth and commitment to its mission, Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a San Francisc...

Factual Olema Oncology, a clinical-stage biopharmaceutical company specialized in developing targeted therapies for breast cancer and other malignancies, has announced significant preclinical findings regarding its inve...

On February 18, 2025, Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer, announce...

Olema Pharmaceuticals Strengthens Workforce with Strategic Inducement Grants Amid Steady Market SurgeSAN FRANCISCO, Jan. 3, 2025 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), an ambitious clinical-stage biopharmaceutica...

The latest clinical results for the combination therapy of palazestrant, an oral selective estrogen receptor degrader (SERD), and ribociclib, a CDK4/6 inhibitor, highlight potential advancements in treating estrogen rec...

Olema Oncology Grants Inducement Stock Options Under Nasdaq Listing Rule 5635(c)(4) Following Promising Research DevelopmentsSAN FRANCISCO, Nov. 04, 2024 Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, Nasdaq: OLM...

Olema Oncology has announced exciting new preclinical combination data that will be showcased at the forthcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. This annual symposium is renow...

San Francisco, Sept. 04, 2024 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for women s cancers, has recently announced the allocation of sto...

Olema Pharmaceuticals Grants Inducement Stock Options to New Employees: Impact on Share PricesSAN FRANCISCO, Aug. 02, 2024 - Olema Pharmaceuticals, Inc. (Olema or Olema Oncology, Nasdaq: OLMA), a clinical-stage biopharm...

Olema Pharmaceuticals, Inc., a renowned clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women s cancers, has recently announced the granting of stock options to several new employ...

: Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on developing targeted therapies for women s cancers, recently announced promising interim results from its ongoing Phase 1b/2 clinical...

Breast cancer remains a significant global health concern, affecting millions of women around the world. Significant advances have been made in the field of oncology, and targeted therapies have emerged as powerful tool...

Olema Oncology Grants Inducement Options to New Employees, Enhancing Workforce and Driving Growth San Francisco, May 02, 2024 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company dedi...

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing targeted therapies for women s cancers, recently announced the granting of stock options to two new employees. This move signifies...

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in targeted therapies for women s cancers, has announced the publication of an important data article in Molecular Cancer Therapeutics. The...

San Francisco-based biopharmaceutical company Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), also known as Olema Oncology, is making waves in the field of women s cancers with its latest announcement. The company has revea...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Dec. 04, 2023 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a leading clinical-stage biopharmaceutical company dedicated to the...

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)Olema Oncology, a leading biopharmaceutical company dedicated to deve...

SAN FRANCISCO, Nov. 02, 2023 - Olema Pharmaceuticals, a leading clinical-stage biopharmaceutical company, has recently announced the granting of stock options to two newly hired employees. With a focus on advancing targ...